THE ‘OZEMPIC’ TRADE: Weight Loss Drugs, Market Cap Gains? A $100-billion global market, rising ‘diabesity’ in India, and a major patent cliff ahead. As semaglutide goes off patent, the race among Indian pharma companies to capture the GLP-1 opportunity LinkedIn Share this: Share on Facebook (Opens in new window) Facebook Share on X (Opens in new window) X Post navigation Reducing imports, strengthening domestic capacity, and supporting allied industries—India’s petrochemical expansion is central to the plastics growth story. At the Plastindia Global CEO Conclave 2026, themed Bharat Next in association with CNBC-TV18, ind – LinkedIn Trump should fear the big X factor of the Iran war: affordability